Head-to-head evidence
Capivasertib vs NTQ1062
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: AKT (inhibitor) · full HR+/HER2- Metastatic Breast Cancer pipeline
Capivasertib
Marketed by AstraZeneca
NCT01625286 · Phase 1/2 · completed
The trial randomized and quadruple-blinded 148 participants and used placebo plus paclitaxel as the control; the Part B primary endpoint was RECIST-defined progression-free survival in 110 patients. Although progression-free survival numerically favored capivasertib (10.9 versus 8.4 months), the primary comparison was not statistically significant (HR 0.80, p=0.308), so the evidence is moderate rather than strong.
Next expected readout: October 2026 · NCT06635447 (registry estimate)
NTQ1062
Developed by Sino Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07393321 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Capivasertib's landscape · NTQ1062's landscape